文献速递妇科肿瘤

转变治疗范式:聚焦高级别浆液性卵巢癌的个体化医疗

Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer.
PubMed 文献 · CA Cancer J Clin · 2025-04-19

高级别浆液性卵巢癌(HGSOC)是最常见且侵袭性强的卵巢癌亚型,约占所有卵巢癌病例的70%,多因早期无症状而确诊时已属晚期。该综述阐述HGSOC的病因、流行病学、分类、发病机制及当前治疗策略,强调分子机制对靶向治疗和个体化多模式治疗的重要性,并关注肿瘤微环境及以患者视角和多样性为中心的治疗决策。

要点

  • HGSOC约占所有卵巢癌病例的70%,是导致该病高死亡率的重要原因。
  • HGSOC肿瘤以体细胞基因拷贝数改变高频为特征,常与DNA同源重组修复缺陷相关。
  • 迄今所有引入HGSOC有效筛查的尝试均未成功。

核心结论

  • 理解分子基础对于在集中化治疗结构中开发靶向治疗和个体化多模式治疗至关重要。
  • 作者的目标是强调将患者视角和多样性置于治疗策略首位的重要性,从而促进真正参与式决策并最终改善患者生活质量。

研究设计与样本

  • 综述,阐述HGSOC的病因、流行病学、分类、发病机制及当前治疗策略,并探讨肿瘤微环境的重要性。

主要发现

  • HGSOC是最常见且侵袭性强的卵巢癌亚型,约占所有卵巢癌病例的70%,显著导致该病高死亡率。
  • 多数患者确诊时已处晚期,癌症已扩散至腹腔,需复杂且密集的手术和化疗干预,随后进行维持治疗。
  • HGSOC肿瘤以体细胞基因拷贝数改变高频为特征,常与DNA同源重组修复缺陷相关。
  • 少数病例与明确遗传综合征相关,但许多病例的具体危险因素和明确病因仍不明确。
  • 迄今所有引入HGSOC有效筛查的尝试均未成功。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

High-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer, accounting for approximately 70% of all ovarian cancer cases and contributing significantly to the high mortality rates associated with this disease. Because of the asymptomatic nature of early stage disease, most patients are diagnosed at advanced stages when the cancer has already spread into the abdominal cavity, requiring complex and intensive surgical and chemotherapeutic interventions followed by maintenance therapies. Although a minority of cases are associated with well defined genetic syndromes, specific risk factors and a clear etiology in many cases remain elusive. HGSOC tumors are characterized by a high frequency of somatic gene copy number alterations, often associated with defects in homologous recombination repair of DNA. All attempts to introduce an effective screening for HGSOC to date have been unsuccessful. This review elucidates the complexities surrounding HGSOC and encompasses its etiology, epidemiology, classification, pathogenesis, and the current array of treatment strategies. Understanding molecular underpinnings is crucial for the development of targeted therapies and personalized multimodal treatment approaches in centralized therapeutic structures. This review also examines the importance of the tumor microenvironment. In addition, the authors' objective is to underscore the critical importance of placing the patient's perspective and diversity at the forefront of therapeutic strategies, thereby fostering a genuinely participatory decision-making process and ultimately improving patient quality of life.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Kordowitzki P, Lange B, Elias KM, et al. Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer. CA Cancer J Clin. 2025. PMID: 40252048. doi:10.3322/caac.70008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。